C1-05: Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial  by Parikh, Purvish M. et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS360
squamous cell ca. 21.4%/14.0%, BAC 2.4%/16.3%, others 
19.1%/6.9%. Median age was 60 years (range 21-74). R was given on 
arm 1 as 2nd line therapy in 64.3% of pts., as 3rd line in 35.7% and on 
arm 2 as 3rd line in 58.1%, as 4th line in 41.9%. 90.6% pts had stage 
IV disease. The trial did not proceed to stage 2 based on RR for 74 pts 
in the efﬁcacy population. Best overall tumor response (arm 1/2 in %): 
conﬁrmed PR (5.3/2.8) and SD (44.7/44.4). Median PFS is 11.3 weeks 
(95% CI: 8.1; 12.4) in arm 1 and 9.7 weeks (7.3; 13.0) in arm 2. Out 
of 42 (arm 1) and 43 (arm 2) patients in the intent-to-treat population, 
22 and 17 respectively achieved a best overall response of SD or better 
(CR+PR): in arm 1 duration of SD observed at the cut-off date ranged 
from 49 days (censored) to 267 days (8 pts have duration of SD>3 
months) and in arm 2 from 68 to 231 days (11 pts have duration of 
SD>3 months). Most frequent AEs (pts, all grades/grade 3&4): stoma-
titis/mucositis (43/5), cough (27/1), dyspnea (33/8), rash (26/0), fatigue 
(25/10), anorexia (25/1), nausea (20/0), anemia (18/3), epistaxis (18/0), 
diarrhea (17/2). IHC analyses of tumor tissue samples conﬁrmed that 
high levels of pEGFR correlate with activation (upregulation) of the 
p-AKT. Detailed analyses will be presented.
Conclusions: 10 mg qd R monotherapy is well tolerated and shows 
limited activity in pretreated advanced NSCLC pts with respect to 
response. R effect in disease control has to be further investigated. 
Combination trials with both standard chemotherapy and targeted 
agents are ongoing.
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Background: Talactoferrin alfa (TLF), an orally active immunomodu-
latory protein, acts at the gut through a novel mechanism of action. In 
animal experiments, TLF bound enterocyte receptors and immune cells 
in the Peyer’s patches, induced DC maturation, and initiated an immu-
nostimulatory cascade in the Gut Associated Lymphoid Tissue (GALT), 
with activation of innate and adaptive immunity. GALT immunomodu-
lation was followed by systemic increases in NK and CTL activity, 
activation of tumor-draining lymph nodes, and cellular inﬁltration of 
distant tumors. Talactoferrin showed anti-cancer activity in preclinical 
experiments and in non-small cell lung cancer (NSCLC) patients in 
Phase 1b studies. Two randomized, placebo-controlled Phase 2 NSCLC 
studies were conducted with TLF as a single agent and combined with 
carboplatin and paclitaxel. The 110-patient combination therapy study 
(previously presented) met its primary endpoint with an improved over-
all response over chemotherapy alone. We now present results from the 
placebo-controlled single agent study.
Methods: 100 Stage IIIB/IV NSCLC patients who had progressed after 
ﬁrst- or second-line therapy were enrolled at 10 leading Indian cancer 
centers, and randomized to receive supportive care plus either oral TLF 
(1.5 g bid) or placebo. TLF/placebo was administered, for up to three 
14-week cycles (12 weeks on, 2 weeks off), in a centrally monitored 
trial. The primary endpoint was overall survival (OS) with 80% power 
to detect an improvement in median OS with a 1-tailed α=0.05. 
Results: All patients had previously received a 1st line platinum based 
regimen; 25 also received 2nd line therapy. The TLF and placebo arms 
enrolled 47 and 53 patients, respectively. Baseline characteristics were 
similar in both groups, including proportion of patients receiving 1 or 2 
prior regimens. All patients were included in the Intent To Treat (ITT) 
analysis. 
The trial met its primary endpoint with a 62% increase in median OS 
(2.3 months; HR 0.69; p<0.05). The talactoferrin effect was also seen 
in relevant subsets, including patients with Stage IIIB or IV disease, 
ECOG 0 or 1, or one/two prior therapies. TLF was well tolerated; 
adverse events (AEs) were generally mild. No drug-related serious AEs 
were reported, and the incidence of total AEs and Grade 3/4 AEs was 
similar in both arms. 
Conclusion: Oral talactoferrin, a promising new anti-cancer agent, 
signiﬁcantly improved survival in patients with refractory NSCLC in 
this randomized, placebo-controlled trial. TLF was well tolerated in this 
population. Given its favorable toxicity proﬁle, TLF may be particu-
larly attractive in refractory patients with poor performance status.
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